Spevigo® (spesolimab-sbzo intravenous infusion)

Covered only for adults (≥18) with FDA‑approved generalized pustular psoriasis flares who meet all criteria: moderate‑to‑severe flare, GPPGA total ≥3 and pustulation subscore ≥2, new/worsening pustules with erythema/pustules affecting ≥5% BSA, and prescribed by or in consultation with a dermatologist—use outside these criteria is excluded. Key requirements: up to two 900 mg IV doses per flare (initial dose, optional second dose 1 week later if needed), reauthorization limits two doses per flare and ≥12 weeks between treatment of new flares, approval duration 3 months, and documentation of age, GPPGA scores, BSA, dermatologist involvement, dosing and dates is required.

"Spevigo is indicated for the treatment of generalized pustular psoriasis flares in adults."

Sign up to see full coverage criteria, indications, and limitations.